Wedbush Comments on Chimerix, Inc.’s Q1 2025 Earnings (NASDAQ:CMRX)
Chimerix, Inc. (NASDAQ:CMRX – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Chimerix in a research report issued to clients and investors on Wednesday, May 1st. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will earn ($0.23) per share for the quarter. Wedbush currently has […]
More Stories
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in...
Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $166.00
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the...
Applied Materials, Inc. (NASDAQ:AMAT) Given Average Recommendation of “Moderate Buy” by Analysts
Applied Materials, Inc. (NASDAQ:AMAT – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-two...
Quest Resource Holding Co. (NASDAQ:QRHC) Director Glenn Culpepper Buys 2,000 Shares
Quest Resource Holding Co. (NASDAQ:QRHC – Get Free Report) Director Glenn Culpepper bought 2,000 shares of the company’s stock in...
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 33,402 Shares of Stock
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a...
Insider Selling: Impinj, Inc. (NASDAQ:PI) COO Sells 826 Shares of Stock
Impinj, Inc. (NASDAQ:PI – Get Free Report) COO Hussein Mecklai sold 826 shares of Impinj stock in a transaction on...